4-Aminopyridine

Results: 41



#Item
21Peripheral and Central Nervous System Drugs Advisory Committee Meeting

Peripheral and Central Nervous System Drugs Advisory Committee Meeting

Add to Reading List

Source URL: www.fda.gov

Language: English
22Microsoft Word - Final Minutes October[removed]doc

Microsoft Word - Final Minutes October[removed]doc

Add to Reading List

Source URL: www.fda.gov

Language: English
23Microsoft Word - DRAFT Agenda Oct142009.doc

Microsoft Word - DRAFT Agenda Oct142009.doc

Add to Reading List

Source URL: www.fda.gov

Language: English
24Microsoft Word - FINAL Questions Oct142009.doc

Microsoft Word - FINAL Questions Oct142009.doc

Add to Reading List

Source URL: www.fda.gov

Language: English
25Health / Medicine / Anatomy / Treatment of multiple sclerosis / 4-Aminopyridine / Multiple sclerosis signs and symptoms / Pathophysiology of multiple sclerosis / Multiple sclerosis / Autoimmune diseases / Neurological disorders

Ampyra To Initiate a Coverage Review, Call[removed]Dalfampridine (Ampyra)  

Add to Reading List

Source URL: statehealthplan.state.nc.us

Language: English - Date: 2013-10-03 14:58:43
26Final Minutes May 6 and 7, 1999 – 2nd Meeting of the Pharmacy Compounding Advisory Committee Food and Drug Administration Center for Drug Evaluation and Research Advisory Committee Conference Room, Room 1092

Final Minutes May 6 and 7, 1999 – 2nd Meeting of the Pharmacy Compounding Advisory Committee Food and Drug Administration Center for Drug Evaluation and Research Advisory Committee Conference Room, Room 1092

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2001-10-16 14:37:06
27© EMSP, European Multiple Sclerosis Platform and DMSG Bundesverband e.V., 2008  Consensus Paper Symptomatic treatment of Multiple Sclerosis

© EMSP, European Multiple Sclerosis Platform and DMSG Bundesverband e.V., 2008 Consensus Paper Symptomatic treatment of Multiple Sclerosis

Add to Reading List

Source URL: www.emsp.org

Language: English - Date: 2011-04-18 09:33:51
28NDA[removed] – FDA Approved Labeling Text dated January 2013 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMPYRA safely and effectively. See full prescribing inf

NDA[removed] – FDA Approved Labeling Text dated January 2013 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMPYRA safely and effectively. See full prescribing inf

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-01-23 15:16:42
29US EPA - Reregistration Eligibility Decision for 4-aminopyridine

US EPA - Reregistration Eligibility Decision for 4-aminopyridine

Add to Reading List

Source URL: www.epa.gov

Language: English - Date: 2007-12-04 13:56:49
30Host: Today, as part of our

Host: Today, as part of our "My Health" series, welre talking about a chronic disabling disease of the nervous system that affects more than two million people worldwide. In fact, about 200 people are diagnosed every wee

Add to Reading List

Source URL: www.fda.gov

Language: English